




Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/021,177
		Filing Date	October 30, 2001
		First Named Inventor	Maria-Luisa Maccacchini
		Group Art Unit	1614
		Examiner Name	William A. Jarvis
Sheet 1 of 6	Attorney Docket Number	SYM 117	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
		5,428,069		Skolnick et al.	06-27-1995
		5,658,782		Amara et al.	08-19-1997
		5,731,348		Gu	03-24-1998
		5,739,284		Hediger et al.	04-14-1998
		5,776,774		Amara et al.	07-07-1998
		5,840,516		Amara et al.	11-24-1998
		5,882,926		Amara et al.	03-16-1999
		5,912,171		Amara et al.	06-15-1999
		5,919,628		Amara et al.	07-06-1999
		5,919,699		Amara et al.	07-06-1999
		5,932,424		Amara et al.	08-03-1999
		5,989,825		Amara et al.	11-23-1999
		6,020,479		Amara et al.	02-01-2000
		6,060,307		Amara et al.	05-09-2000
		6,074,828		Amara et al.	06-13-2000

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office. ³	Number ⁴	Kind Code ⁵ (if known)		
		EP	0 342 558		Searle & Co.	11-23-1989
		EP	0 913 389		Nippon Chemiphar Co.	05-06-1999
		PCT	WO 96/25387		Symphony Pharm. Inc.	08-22-1996
		PCT	WO 98/38208		Bearsden Bio Inc.	09-03-1998
		PCT	WO 99/38839		Kumugai Toshihito	08-05-1999
		PCT	WO 00/27374		Stys	05-18-2000

Examine Signature		Date Considered	
-------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/021,177
		Filing Date	October 30, 2001
		First Named Inventor	Maria-Luisa Maccacchini
		Group Art Unit	1614
		Examiner Name	William A. Jarvis
Sheet 3 of 6	Attorney Docket Number	SYM 117	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		ARRIZA, et al., "Excitatory amino acid transporter 5, a retinal glutamate transporter coupled to a chloride conductance" <i>Proc. Natl. Acad. Sci. U.S.A.</i> 94(8): 4155-4160 (1997).	
		ARRIZA, et al., "Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex" <i>J. Neurosci.</i> 14(9): 5559-5569 (1994).	
		BAKER, et al., "4-alkylidenyl glutamic acids, potent and selective GluR5 agonists," <i>Bioorg. Med. Chem. Lett.</i> 10(16): 1807-1810 (2000).	
		BRIDGES, et al., "A pharmacological review of competitive inhibitors and substrates of high-affinity, sodium-dependent glutamate transport in the central nervous system" <i>Curr. Pharmaceut. Des.</i> 5(5): 363-379 (1999).	
		BRAÜNER-OSBORNE, et al., "Molecular pharmacology of 4-substituted glutamic acid analogues at ionotropic and metabotropic excitatory amino acid receptors," <i>Eur. J. Pharm.</i> 335(2-3): R1-R3 (1997).	
		CARROLL, et al., "Regional distribution of low affinity kainate receptors in brain of Macaca fascicularis determined by autoradiography using [3H](2S,4R)-4-methylglutamate" <i>Neurosci. Lett.</i> 255(2): 71-74 (1998).	
		FAIRMAN, et al., "An excitatory amino-acid transporter with properties of a ligand-gated chloride channel," <i>Nature</i> 375(6532): 599-603 (1995).	
		FURUTA et al., "Glutamate transporter protein subtypes are expressed differentially during rat CNS development," <i>J. Neurosci.</i> 17(21): 8363-8375 (1997).	
		GEGELASHVILI, et al., "High affinity glutamate transporters: regulation of expression and activity" <i>Mol Pharmacol</i> 52(1):6-15 (1997).	
		GU, et al., "Diastereoselective synthesis of (2S,4R)-4-methylglutamic acid (SYM 2081): a high affinity and selective ligand at the kainate subtype of glutamate receptors," <i>Bioorg. Med. Chem. Lett.</i> 5(17): 1973-1976 (1995).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-95)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		Application Number	10/021,177
		Filing Date	October 30, 2001
		First Named Inventor	Maria-Luisa Maccacchini
		Group Art Unit	1614
		Examiner Name	William A. Jarvis
Sheet 4 of 6		Attorney Docket Number	SYM 117

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		GU, et al., "Synthesis, resolution, and biological evaluation of the four stereoisomers of 4-methylglutamic acid: selective probes of kainate receptors," <i>J Med Chem</i> 38(14):2518-20 (1995).	
		KANAI, et al., "Primary structure and functional characterization of a high-affinity glutamate transporter" <i>Nature</i> 360(6403): 467-471 (1992).	
		KRASNOV, et al., "Stereo-directed synthesis of 4 hydroxy-glutamic acid enantiomers and the study of their inhibiting properties with respect to glutamine synthetase," <i>Khimiko-Farmatsevticheskii Zhurnal</i> 18(6): 655-659 (1984), abstract only.	
		KROGSGAARD-LARSEN, et al., "Design of excitatory amino acid receptor agonists, partial agonists and antagonists: ibotenic acid as a key lead structure," <i>Eur. J. Med. Chem.</i> 31(7): 515-537 (1996).	
		LI, et al., "The Na ⁺ -dependent binding of [3H]L-aspartate in thaw-mounted sections of rat forebrain" <i>Exp. Brain Res.</i> 97(3): 415-422 (1994).	
		LIPTON, et al., "Excitatory amino acids as a final common pathway for neurologic disorders," <i>N Engl J Med</i> 330(9):613-22 (1994).	
		MCLENNAN, "Actions of excitatory amino acids and their antagonism," <i>Neuropharmacol.</i> 13(6): 449-454 (1974).	
		PEDREGAL, et al., "4-alkyl- and 4-cinnamylglutamic acid analogues are potent GluR5 kainate receptor agonists," <i>J. Med. Chem.</i> 43(10): 1958-1968 (2000).	
		PELLETIER & HESSON, "A mild preparation of amino acid N-acylsulfonamides," <i>Synlett</i> 11: 1141-1142 (1995).	
		PINES, et al., "Cloning and expression of a rat brain L-glutamate transporter" <i>Nature</i> 360(6403): 464-467 (1992).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/021,177
		Filing Date	October 30, 2001
		First Named Inventor	Maria-Luisa Maccacchini
		Group Art Unit	1614
		Examiner Name	William A. Jarvis
Sheet 5 of 6	Attorney Docket Number	SYM 117	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		ROBINSON, et al., "Heterogeneity and functional properties of subtypes of sodium-dependent glutamate transporters in the mammalian central nervous system" <i>Adv. Pharmacol.</i> 37: 69-115 (1997).	
		ROTHSTEIN, et al., "Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate" <i>Neuron</i> 16(3):675-686 (1996).	
		SHIMAMOTO, et al., "DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters" <i>Mol. Pharmacol.</i> 53(2): 195-201 (1998).	
		STARR, "Glutamate/Dopamine D ₁ /D ₂ balance in the basal ganglia and its relevance to Parkinson's disease," <i>Synapse</i> 19(4): 264-293 (1995).	
		STORCK, et al., "Structure, expression, and functional analysis of a Na(+)-dependent glutamate/aspartate transporter from rat brain." <i>Proc. Natl. Sci. U.S.A.</i> 89(22): 10955-10959 (1992).	
		TA, et al., "SYM-2081 a kainate receptor antagonist reduces allodynia and hyperalgesia in a freeze injury model of neuropathic pain," <i>Brain Res.</i> 858(1): 106-120 (2000).	
		TOMS, et al., "A novel kainate receptor ligand [3H]-(2S,4R)-4-methylglutamate: pharmacological characterization in rabbit brain membranes" <i>Neuropharmacology</i> 36(11-12): 1483-1488 (1997).	
		TRIST, "Excitatory amino acid agonists and antagonists: pharmacology and therapeutic applications," <i>Pharm. Acta Helvet.</i> 74(2-3): 221-229 (2000).	
		VANDENBERG, et al., "Contrasting modes of action of methylglutamate derivatives on the excitatory amino acid transporters, EAAT1 and EAAT2" <i>Mol. Pharmacol.</i> 51(5): 809-815 (1997).	
		VANDENBERG, "Molecular pharmacology and physiology of glutamate transporters in the central nervous system," <i>Clin. Exp. Pharmacol. Physiol.</i> 25(6): 393-400 (1998).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
		Application Number	10/021,177
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	October 30, 2001
		First Named Inventor	Maria-Luisa Maccacchini
		Group Art Unit	1614
		Examiner Name	William A. Jarvis
		Attorney Docket Number	SYM 117
Sheet	6		

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		WINTER & UEDA, "Glutamate uptake system in the presynaptic vesicle: glutamic acid analogs as inhibitors and alternate substrates," <i>Neurochem. Res.</i> 18(1): 79-85 (1993).	
		ZHOU, et al., "(2S,4R)-4-methylglutamic acid (SYM 2081): a selective, high-affinity ligand for kainate receptors" <i>J. Pharmacology Exper. Therapeutics</i> 280(1):422-427 (1997).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.